Capital Investment Advisors LLC Sells 7,335 Shares of Johnson & Johnson (NYSE:JNJ)

Capital Investment Advisors LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 1.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 408,413 shares of the company’s stock after selling 7,335 shares during the quarter. Johnson & Johnson comprises 1.2% of Capital Investment Advisors LLC’s investment portfolio, making the stock its 19th largest holding. Capital Investment Advisors LLC’s holdings in Johnson & Johnson were worth $59,065,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Trust Co. of Toledo NA OH raised its position in shares of Johnson & Johnson by 8.5% during the 4th quarter. Trust Co. of Toledo NA OH now owns 44,208 shares of the company’s stock valued at $6,393,000 after acquiring an additional 3,471 shares during the last quarter. Fiduciary Alliance LLC grew its stake in shares of Johnson & Johnson by 7.1% during the fourth quarter. Fiduciary Alliance LLC now owns 78,738 shares of the company’s stock worth $11,387,000 after purchasing an additional 5,245 shares during the period. Crescent Sterling Ltd. increased its holdings in Johnson & Johnson by 0.3% in the fourth quarter. Crescent Sterling Ltd. now owns 23,239 shares of the company’s stock valued at $3,361,000 after purchasing an additional 72 shares during the last quarter. Clark & Stuart Inc bought a new position in Johnson & Johnson during the fourth quarter worth about $7,647,000. Finally, Aprio Wealth Management LLC grew its position in shares of Johnson & Johnson by 2.9% during the 4th quarter. Aprio Wealth Management LLC now owns 8,055 shares of the company’s stock worth $1,165,000 after buying an additional 225 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Guggenheim boosted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Citigroup dropped their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Wolfe Research initiated coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. Finally, Royal Bank of Canada lifted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $174.71.

Johnson & Johnson Stock Up 0.4 %

Shares of JNJ stock traded up $0.55 during trading on Monday, reaching $142.61. The company’s stock had a trading volume of 2,828,834 shares, compared to its average volume of 7,187,380. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The business has a fifty day moving average price of $149.67 and a 200-day moving average price of $156.11. The company has a market cap of $343.35 billion, a price-to-earnings ratio of 20.64, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.66 EPS. Analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.48%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.